Dr. Diehn is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
875 Blake Wilbur Dr
Dept of Radiation Oncology Mc5847
Stanford, CA 94305Phone+1 650-723-6171
Education & Training
- Stanford Health Care-Sponsored Stanford UniversityResidency, Radiation Oncology, 2005 - 2009
- Stanford Health Care-Sponsored Stanford UniversityInternship, Internal Medicine, 2004 - 2005
- Stanford University School of MedicineClass of 2004
Certifications & Licensure
- CA State Medical License 2005 - 2025
- American Board of Radiology Radiation Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
Clinical Trials
- Individualized Lung Tumor Stereotactic Ablative Radiotherapy (iSABR) Start of enrollment: 2011 Oct 21
- Molecular and Cellular Analysis of Breast Cancer Start of enrollment: 2014 Sep 01
- Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC Start of enrollment: 2021 Aug 25
Publications & Presentations
PubMed
- Association between Locoregional Failure and NFE2L2/KEAP1/CUL3 Mutations in NRG/RTOG 9512: A Randomized Trial of Radiation Fractionation in T2N0 Glottic Cancer.Li Guan, Pedro A Torres-Saavedra, Xiaobei Zhao, Michael B Major, Brittany J Holmes
Clinical Cancer Research. 2024-12-10 - Phase II Trial of Regorafenib and Oral Methotrexate in Previously Treated Advanced-Mutant NSCLC.Jacqueline V Aredo, Heather A Wakelee, Kavitha J Ramchandran, Joel W Neal, Maximilian Diehn
JTO Clinical and Research Reports. 2024-12-01 - Response to Letter to the Editor.Soyeong Jun, Nikhil A Shukla, Nasser H Hanna, Maximilian Diehn
Journal of Thoracic Oncology. 2024-12-01
Abstracts/Posters
- Circulating DNA for Molecular Response Prediction, Characterization of Resistance Mechanisms and Quantification of CAR T-Cells during Axicabtagene Ciloleucel TherapyMaximilian Diehn, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Interim Circulating Tumor DNA As a Prognostic Biomarker in the Setting of Interim PET-Based Adaptive Therapy for DLBCLMaximilian Diehn, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- An Atlas of Clinically-Distinct Tumor Cellular Ecosystems in Diffuse Large B Cell LymphomaMaximilian Diehn, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Press Mentions
- Can Cancer Be Found in a Blood Test?February 8th, 2023
- Tool Can Reveal Cancer Subtypes by Cell Communities They’re Found InOctober 28th, 2021
- Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate CancerMarch 30th, 2020
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: